Johnston, A. N.
Bu, W.
Hein, S.
Garcia, S.
Camacho, L.
Xue, L.
Qin, L.
Nagi, C.
Hilsenbeck, S. G.
Kapali, J.
Podsypanina, K.
Nangia, J.
Funding for this research was provided by:
National Institutes of Health (R01CA205594, P50CA186784, T32GM088129, T32AG000183)
U.S. Department of Defense (CDMRP BC123368)
Susan G. Komen for the Cure (PDF15330612)
Dan L. Duncan Cancer Center, Baylor College of Medicine (P30CA125123)
Cancer Prevention and Research Institute of Texas (RP101499)
Article History
Received: 30 November 2017
Accepted: 11 April 2018
First Online: 19 May 2018
Ethics approval
: All animals were handled according to the animal protocol approved by the Institutional Animal Care and Use Committee (IACUC) at Baylor College of Medicine.
: Dr. Li receives the ruxolitinib and research support from Incyte Corp. The authors declare that they have no other competing interests
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.